Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.

开始日期2026-07-31

申办/合作机构

Centre Hospitalier Universitaire de Nimes

CTIS2024-513298-29-00

/ Recruiting临床2期IIT

Osteoarticular infections on equipment: impact of three probabilistic antibiotic therapy strategies on the digestive microbiota and gastrointestinal colonization with multidrug-resistant bacteria

开始日期2026-05-26

申办/合作机构

Centre Hospitalier Universitaire de Nice

ChiCTR2500108292

/ RecruitingN/AIIT

Efficacy and Mechanism of Ceftobiprole in Treating Mycobacterium abscessusLung Disease

开始日期2025-06-01

申办/合作机构-

100 项与头孢比罗酯钠相关的临床结果

登录后查看更多信息

100 项与头孢比罗酯钠相关的转化医学

登录后查看更多信息

100 项与头孢比罗酯钠相关的专利（医药）

登录后查看更多信息

342

项与头孢比罗酯钠相关的文献（医药）

2026-12-31·Emerging Microbes & Infections

Staphylococcus pettenkoferi : an underrecognized species with clinically relevant antimicrobial resistance. A comprehensive genomic European study

Article

作者: Rwayane, Kenza ; Morsli, Madjid ; Piau-Couapel, Caroline ; Corvec, Stéphane ; Denis, Olivier ; Pantel, Alix ; Lavigne, Jean-Philippe ; Dunyach-Remy, Catherine ; Kahl, Barbara C. ; Salipante, Florian ; François, Patrice ; Laurent, Frédéric ; Curtil-Dit-Galin, Matthieu ; Söderquist, Bo ; Magnan, Chloé ; Cattoir, Vincent

Staphylococcus pettenkoferi has increasingly been reported as a human pathogen, with virulence potential recently confirmed in vivo. However, its genomic diversity and antimicrobial resistance remain insufficiently characterized. This study, conducted within the PETTENK-OS project of the ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS), aimed to characterize the genomic diversity and resistome of this underrecognized coagulase-negative staphylococcus (CoNS). Whole-genome sequencing was performed on 61 European clinical isolates (mainly bloodstream infections and osteomyelitis) from 17 hospitals in five countries, plus two reference strains. Antimicrobial susceptibility profiles were determined by disk diffusion and broth microdilution (2025 EUCAST breakpoints). Phylogenetic analyses clustered the 63 isolates into two major clades: Clade I (n = 51; subclades I-A, n = 47, and I-B, n = 4) and Clade II (subclades II-A, n = 8, and II-B, n = 3). Susceptibility rates were below 70% for cefoxitin, erythromycin, and levofloxacin, whereas high susceptibility (>90%) was observed for vancomycin, teicoplanin, dalbavancin, aminoglycosides, oxazolidinones, trimethoprim-sulfamethoxazole, fusidic acid, and tetracycline. Nearly all isolates (92.1%) were fosfomycin-resistant. Daptomycin MIC50/90 values (1/2 mg/L) were elevated, including eight resistant isolates carrying mutations in walKR, cls1, and/or cls2 genes. Twenty-two isolates (35.4%) were multidrug-resistant, and 18 (28.6%) were methicillin-resistant, all in subclade I-A and mecA-positive within SCCmec type IV. This study provides a comprehensive genomic and phenotypic assessment of antimicrobial resistance in S. pettenkoferi, revealing widespread multidrug-resistant lineages, including ceftobiprole- and daptomycin-resistant isolates across distinct clades. These findings underscore the need for continued surveillance and improved diagnostics for this increasingly encountered CoNS species.

2026-12-01·INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Pharmacokinetic and pharmacokinetic/pharmacodynamic (PK/PD) considerations of ceftaroline and ceftobiprole for the treatment of Staphylococcus aureus infections: A systematic review

Review

作者: Colaneri, Marta ; Gori, Andrea ; Abdul-Aziz, Mohd-Hafiz ; Ulldemolins, Marta ; Soriano, Alex ; Sguazzini, Enrico ; Maddalena, Donatella ; Sime, Fekade B ; Roberts, Jason A ; Genovese, Camilla

OBJECTIVES:

Ceftaroline and ceftobiprole are fifth-generation cephalosporins with activity against methicillin-resistant Staphylococcus aureus. The aims of this review are to summarize pharmacokinetics and pharmacokinetics/pharmacodynamics evidences on these drugs in healthy volunteers and across different patient populations, their targets associated with clinical efficacy, and the probability of target attainment for different dosing strategies.

METHODS:

A systematic review was performed using MEDLINE (Pubmed), Embase, Web of Science and Scopus libraries. Peer-reviewed studies reporting the pharmacokinetics of ceftaroline and ceftobiprole and/or their pharmacokinetics/pharmacodynamics in S. aureus infections were included. Screening, data extraction, and quality assessment were performed independently by two reviewers.

RESULTS:

Thirty-one studies for ceftaroline and 22 studies for ceftobiprole met the inclusion criteria. Literature appraisal revealed substantial pharmacokinetic variability in special populations, particularly critically ill patients, with increased volumes of distribution and variable clearance. In patients without severe infections, standard dosing generally achieved high probabilities of attaining pre-clinical pharmacokinetic/pharmacodynamic targets for bacteriostasis, 1-log₁₀ and 2-log₁₀ kill (20%, 26%, and 37% fT_>MIC for ceftaroline, 8.8%, 13.5%, and 23% for ceftobiprole) up to the clinical breakpoints. By contrast, in patients with altered pharmacokinetics or deep-seated infections, intensified dosing and prolonged infusions were often required to achieve plasma and tissue pharmacokinetic/pharmacodynamic targets, particularly for stringent endpoints such as 100% fT_>MIC.

CONCLUSIONS:

Ceftaroline and ceftobiprole pharmacokinetics are highly variable in hospitalized patients, potentially compromising attainment of stringent pharmacokinetic/pharmacodynamic targets for S. aureus infections. Intensified doses and prolonged infusions may therefore be necessary to ensure adequate drug exposure.

2026-09-01·TALANTA

Feasibility verification of fingerstick capillary microsampling replacing venipuncture for therapeutic drug monitoring of 12 antibiotics using a rapid LC-MS/MS assay

Article

作者: Jiang, Yueping ; Deng, Ziwei ; Zhang, Wendan ; Wang, Aimin ; Li, Huanhuan ; Shu, Xiangjin ; Chen, Feng ; Qiu, Chengfeng ; Yang, Xiaoxia ; Tan, Yayun

Therapeutic drug monitoring (TDM) is essential for optimizing antimicrobial therapy and curbing resistance, yet conventional venipuncture limits its widespread application due to invasiveness and operational complexity. This study aimed to establish a rapid LC-MS/MS method for simultaneous quantification of 12 antimicrobial agents and to evaluate the feasibility of using fingertip capillary serum as an alternative to venous serum for TDM. A liquid chromatography tandem mass spectrometry method was developed and validated for the simultaneous quantification of vancomycin, linezolid, voriconazole, sulfamethoxazole, trimethoprim, piperacillin, cefoperazone, ceftazidime, ceftobiprole, meropenem, imipenem, and cilastatin in human serum. The method was applied to analyze 379 paired clinical samples (fingertip serum versus venous serum), and agreement between the two sampling approaches was assessed using Deming regression and Bland Altman analysis. The method required only 10 μL of serum and a total run time of 4 min. Deming regression slopes ranged from 0.910 to 1.017. Bland Altman analysis showed that 100.0% of the data points fell within ±20.0% limits of agreement for all antibiotics except vancomycin (96.7%) and cilastatin (97.5%). This study provides large scale clinical evidence demonstrating high concordance between fingertip serum and venous serum concentrations for 12 antimicrobial agents. By directly obtaining serum, this approach fundamentally avoids the hematocrit effect and matrix conversion issues inherent in whole blood microsampling, offering a minimally invasive TDM strategy fully aligned with the gold standard matrix. This strategy is particularly suitable for special populations such as children, the elderly, and critically ill patients.

244

项与头孢比罗酯钠相关的新闻（医药）

2026-10-23

·北京医学感染与传染研究

国际抗微生物制剂杂志 67卷 12期（2026年10月23日本周5/38篇更新/进展中）

International Journal of Antimicrobial Agents Volume 67, Issue 12 国际抗微生物制剂杂志 67卷 12期 https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/12 Hot Topic（热点） 1. The pitfalls of HIV-1 DNA resistance genotyping: What it can and cannot tell us HIV-1 DNA 耐药基因分型的局限：其所能提供和不能提供的信息 Gilbert Mchantaf, Laurence Morand-Joubert, Antoine Cheret, Laurent Hocqueloux, Véronique Avettand-Fenoel Article 108026 2. Antibacterial dose optimisation in patients with febrile neutropenia: Are we targeting the right patients and the right endpoints? 发热伴中性粒细胞减少症患者的抗菌药物剂量优化：我们是否选对了目标人群与研究终点？ João Paulo Telles, Birgit Koch Article 108024 Klebsiella pneumoniae（肺炎克雷伯菌） 3. Remodelling the host immune microenvironment in carbapenem-resistant Klebsiella pneumoniae: An evidence-graded framework for host-directed intervention 耐碳青霉烯肺炎克雷伯菌感染中宿主免疫微环境重塑：宿主导向干预的证据分级框架 Xiaolin Liang, Junwei Wang, Chao Liu, Qingyuan Gao, ... Yan He Article 108000 Reviews（综述） 4. Pharmacokinetic and pharmacokinetic/pharmacodynamic (PK/PD) considerations of ceftaroline and ceftobiprole for the treatment of Staphylococcus aureus infections: A systematic review 头孢洛林与头孢比罗治疗金黄色葡萄球菌感染的药代动力学及药代/药效学（PK/PD）考量：系统评价 Camilla Genovese, Marta Colaneri, Enrico Sguazzini, Donatella Maddalena, ... Marta Ulldemolins Article 107959 5. Antibiotic resistance in Helicobacter pylori: pathogenic mechanisms and eradication barriers 幽门螺杆菌的抗生素耐药性：致病机制与根除障碍 Meenakshi Kandpal, Siddharth Singh, Harshita Shrivastava, Himanshi Jindal, ... Hem Chandra Jha Article 107981 6. Clinical pharmacology and therapeutic considerations of isavuconazole in special populations: A narrative review 艾沙康唑在特殊人群中的临床药理学特征与治疗考量：叙述性综述 Shichao Zhu, Rongsong Xia, Jing Yang, Fei Tang, ... Xuewen Qiu Article 108005 7. Nipah virus: An exceptionally virulent emerging zoonotic pathogen 尼帕病毒：一种高毒力新发人兽共患病病原体 Hao Sun, Xin Yuan, Jinyan Li, Xitang Li, ... Guangcai Duan Article 107990 8. Examining the global antimicrobial resistance surveillance landscape in food-producing animals 食用动物全球抗菌药物耐药性监测体系现状探析 Vika Li, Shaina Craig, Shabbir Simjee Article 108008 9. Convergence of carbapenem resistance and hypervirulence in Klebsiella pneumoniae in Europe: A systematic review 欧洲肺炎克雷伯菌中碳青霉烯耐药与高毒力的融合现象：一项系统综述 Axelle Vasseur, Marie Fave, Sarah Ronsin, Thierry Naas, ... Agnès B. Jousset Article 108028 10. Advancing bacteriophage therapy through encapsulation: An evidence-based scoping review from animal trials 通过包封技术推进噬菌体疗法：基于动物试验的循证范围综述 Ismail Hossain, Sam Abraham, Jasim M. Uddin Article 108032 Full Length Articles（全文论著） 11. Proteomics reveals the mechanism by which sodium oleate decreases Escherichia coli susceptibility to gentamicin 蛋白质组学揭示油酸钠降低大肠埃希菌对庆大霉素敏感性的机制 Lvyuan Fan, Jingyun Wu, Ziyi Zhang, Liting Cai, ... Guozhu Ye Article 107989 12. Real-world use of liposomal amphotericin B: A large retrospective, observational, multicentre study 脂质体两性霉素 B 在现实中的应用：一项大型回顾性观察性多中心研究 Claudia Bartalucci, Daniele Roberto Giacobbe, Marco Muccio, Silvia Sisto, ... Giulia Viero Article 107952 13. Global burden of bacterial antimicrobial resistance among children under 5 years 1990−2021: A systematic analysis with forecasts to 2050 1990—2021年全球5岁以下儿童细菌耐药性疾病负担：系统分析及至2050年预测 Shanshan Wang, Fei Xie, Shaowei Sang Article 107995 14. Evaluation of vancomycin bolus/standard and continuous infusion on nephrotoxicity in a rat model 大鼠模型中万古霉素推注/常规给药与持续输注方案的肾毒性评价 Sylwia Marianski, Gwendolyn M. Pais, Colin Jeantet, Renz Paulo Melicor, ... Marc H. Scheetz Article 107988 15. Prevalence of third-generation cephalosporin-resistant Salmonella in animals in China: The key role of ESBL, AmpC, and other β-lactamase strains in the genome 我国动物源第三代头孢菌素耐药沙门菌流行情况：ESBL、AmpC 及其他 β- 内酰胺酶菌株在基因组中的关键作用 Fangqin Liu, Lu Zhang, Qi Zhao, Min Cheng, ... Chunping Zhang Article 107992 16. Real-world safety signals of fluoroquinolone-associated peripheral neuropathy: Analysis of US and Canadian databases combined with mechanistic exploration 氟喹诺酮类药物相关周围神经病变在现实中的安全信号：美、加数据库联合分析及机制探讨 Bingjian Guo, Ziwei Zou, Junfei Lu, Shimei Tan, Lingyan Mai Article 107993 17. Appropriate therapy and survival in carbapenem-resistant Enterobacterales bacteraemia: A multicentre cohort study on epidemiology and risk factors 碳青霉烯耐药肠杆菌科细菌菌血症的恰当治疗与生存率：一项关于流行病学及危险因素的多中心队列研究 Yae Jee Baek, Se Yoon Park, Jung Ho Kim, Hye Seong, ... Yoon Soo Park Article 108001 18. Ecological antagonism constrains receptor-diverse phage cocktail efficacy against multidrug-resistant Enterobacter hormaechei 生态拮抗作用限制受体多样性噬菌体鸡尾酒制剂对多重耐药霍氏肠杆菌的疗效 Bai-Ling Zhang, Ming-Yu Jiang, Xiu-Zhen Chen, Xiao-Qi Yang, ... Wei Chen Article 108004 19. Genomic epidemiology and resistance determinants of Pseudomonas aeruginosa in bronchiectasis across China: A multicentre study 全国支气管扩张患者铜绿假单胞菌的基因组流行病学及耐药决定因子研究：一项多中心研究 Linlin Xu, Qing Chen, Aikuang Ma, Kang Xu, ... Xiaoli Wang Article 108010 20. Pharmacovigilance signals and regional burden of antibiotic-associated Clostridioides difficile infection: A pharmacovigilance study and Global Burden of Disease Study 2023 药物警戒信号与抗生素相关艰难梭菌感染的区域疾病负担：一项药物警戒研究及 2023 年全球疾病负担研究 Dain Y. Kim, Hyunjeong Kim, Hyunyi Yoo, Hyoin Shin, ... Dong Keon Yon Article 108013 21. Aztreonam-avibactam activity against Enterobacterales from Asia Pacific and Latin American medical centres: Summary of 5 years of surveillance prior to clinical use (2020–2024) 氨曲南 - 阿维巴坦对亚太及拉美地区医疗机构肠杆菌目细菌的抗菌活性：临床应用前 5 年监测汇总（2020–2024） Helio S. Sader, Rodrigo E. Mendes, John H. Kimbrough, Krisztina M. Papp-Wallace, Mariana Castanheira Article 108003 22. Vancomycin population pharmacokinetics and optimized dosing in critically ill infants and children 危重症婴幼儿万古霉素群体药代动力学与优化给药方案 Tavey Dorofaeff, Xin Liu, Emmanuel Novy, Mark G. Coulthard, ... Jason A. Roberts Article 108006 23. Pulmonary penetration of intravenous rifabutin in healthy participants: A multiple-dose pharmacokinetic study 健康受试者静脉输注利福布汀的肺组织穿透性：一项多剂量药代动力学研究 Valentin al Jalali, Anselm Jorda, Lena Pracher, Amelie Leutzendorff, ... Markus Zeitlinger Article 108014 24. A clinical prediction model to support risk-adapted fibrinogen monitoring during tigecycline therapy: Multicentre development and validation 替加环素治疗期间用于风险分层纤维蛋白原监测的临床预测模型：多中心构建与验证 Jinlin Guo, Xinfeng Cai, Yayu Huo, Hongping Wen, ... Ruigang Hou Article 108012 Short Communications（短篇通讯） 25. Long-term treatment durability and safety after switching to bictegravir/emtricitabine/tenofovir alafenamide in real-world practice: a 144-week update from the BICTEL cohort 真实世界中换用比克替拉韦/恩曲他滨/丙酚替诺福韦后的长期疗效持久性与安全性：BICTEL队列144周更新数据 Luca Bortolani, Riccardo Donà, Antonietta Impellizzeri, Vlad Racolta, ... Gabriella d'Ettorre Article 107991 26. Daptomycin or linezolid versus vancomycin for the treatment of vancomycin-susceptible Enterococcus faecium bloodstream infections 达托霉素或利奈唑胺对比万古霉素治疗万古霉素敏感型屎肠球菌血流感染 Samantha Poloni, Timothée Klopfenstein, Adrien Biguenet, Mathieu Blot, ... Anne-Sophie Brunel Article 107994 27. Silent carriage of tigecycline- and carbapenem-resistant Klebsiella quasipneumoniae co-harbouring tet(X4) and blaNDM-1 in healthy individuals in China 国健康人群中携带tet(X4)与blaNDM-1基因的耐替加环素及碳青霉烯类准肺炎克雷伯菌的静默携带现象 Jing Wang, Zelin Yan, Heng Shen, Ling Xin, ... Rong Zhang Article 108009 28. Caspofungin pharmacokinetics in a child undergoing continuous veno-venous haemodiafiltration: A case report 接受连续性静脉 - 静脉血液透析滤过治疗患儿的卡泊芬净药代动力学：1 例病例报告 Noémie de Cacqueray, Agathe Béranger, Leo Froelicher Bournaud, Mathilde Grapin, ... Mehdi Oualha Article 108002 Letters to the Editor（致编辑信） 29. Comment on "stepwise within-host evolution of a blaCTX-M-27-positive Klebsiella pneumoniae clone under changing antimicrobial pressures leading to enhancement of β-lactam resistance" 评述《抗菌药物压力变化下产blaCTX-M-27肺炎克雷伯菌克隆株在宿主体内逐步进化并增强β内酰胺耐药性》 Evy Diah Woelansari, Sari Luthfiyah, Juliana Christyaningsih, Tacik Idayanti, Anita Dwi Anggraini Article 107987 30. blaNDM-4-carrying Klebsiella pneumoniae: an uncommon but epidemiologically informative signal in public genomes 携带blaNDM-4基因的肺炎克雷伯菌：公开基因组中一种少见但具流行病学提示价值的信号 Yan Feng, Yu Feng, Xiaoting Hua, Chao Zhuo, Zhiyong Zong Article 107982 31. Comment on “Aztreonam–avibactam pharmacokinetics during extracorporeal membrane oxygenation support: First insights from a case report” 对《体外膜肺氧合支持期间氨曲南 - 阿维巴坦的药代动力学：一则病例报告的初步探索》的评论 Guanghui Chen, Haibo Lei, Liang Long, Xiang Liu Article 107961 32. Comment on “The antiarrhythmic drugs dronedarone and amiodarone exhibit potent in vitro and in vivo activity against clostridioides difficile” 对《抗心律失常药物决奈达隆与胺碘酮在体内外均具有强大的艰难梭菌抑制活性》的评论 Zareena Begum Shaik, Thirupathi Gorre, Harikiran Lingabathula Article 107976 33. In reply to the letter to editor regarding ‘discrepancy between WGS-based genotypic and phenotypic drug susceptibility testing of first and second-line drugs for Mycobacterium tuberculosis: Limited impact of unknown resistance mechanisms’ 回复致编辑信：《结核分枝杆菌一线与二线药物基于全基因组测序的基因型药敏试验与表型药敏试验结果不一致：未知耐药机制的影响有限》 Peng Xu, Qian Gao Article 107999 34. In Reply to the Letter to Editor Regarding Tissue Pharmacokinetics of Antifungal Drugs: A Review 回复致编辑的信：《抗真菌药物的组织药代动力学：综述》 Felix Bergmann, Marlene Prager, Markus Zeitlinger Article 107996 35. In reply to letter to editor regarding ``a multicenter, randomised, double-blind, imipenem/cilastatin-controlled clinical study of cefiderocol for the treatment of complicated urinary tract infections caused by Gram-negative pathogens in Chinese adults'' 回复致编辑的信：《头孢地尔治疗中国成人革兰阴性菌所致复杂性尿路感染的多中心、随机、双盲、以亚胺培南 / 西司他丁为对照的临床研究》 Jinyi Yuan, Deyong Fan, Henglan Wu, Bei Jia, ... Yingyuan Zhang Article 107983 36. In reply to the Letter to the Editor regarding “Disrupting bacterial metabolism by targeting LDH reverses aminoglycoside resistance in Streptococcus suis” 针对《靶向乳酸脱氢酶干扰细菌代谢可逆转猪链球菌对氨基糖苷类药物的耐药性》一文致编者信的回复 Yang Wang, Shuji Gao, Baobao Liu, Yuxin Wang Article 108007 37. Comment on “Discrepancy between WGS-based genotypic and phenotypic drug susceptibility testing of first- and second-line drugs for Mycobacterium tuberculosis: Limited impact of unknown resistance mechanisms” 对《结核分枝杆菌一线及二线药物基于全基因组测序的基因型药敏试验与表型药敏试验结果不一致性：未知耐药机制的影响有限》一文的述评 Manish R. Bhise, Akshay Akotkar, Shweta Bhandari, Kuldip V. Gite Article 107997 38. Response to the Comment on ‘Burden and global distribution of antimicrobial resistance in nonbloodstream infections among adults with cirrhosis: A systematic review and proportional meta-analysis’ 针对《肝硬化成人非血流感染中抗菌药物耐药负担及全球分布：一项系统综述与比例 Meta 分析》一文评述的回复 Ellis K. Paintsil, Cansu Ozdemir, Tuhin Paul, Kasope Egoh, ... Debbie L. Shawcross Article 108019

2026-10-21

·北京医学感染与传染研究

国际抗微生物制剂杂志 67卷 12期（2026年10月21日1/34篇更新/进展中）

International Journal of Antimicrobial Agents Volume 67, Issue 12 国际抗微生物制剂杂志 67卷 12期 https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/12 Klebsiella pneumoniae（肺炎克雷伯菌） 1. Remodelling the host immune microenvironment in carbapenem-resistant Klebsiella pneumoniae: An evidence-graded framework for host-directed intervention 耐碳青霉烯肺炎克雷伯菌感染中宿主免疫微环境重塑：宿主导向干预的证据分级框架 Xiaolin Liang, Junwei Wang, Chao Liu, Qingyuan Gao, ... Yan He Article 108000 Reviews（综述） 2. Pharmacokinetic and pharmacokinetic/pharmacodynamic (PK/PD) considerations of ceftaroline and ceftobiprole for the treatment of Staphylococcus aureus infections: A systematic review 头孢洛林与头孢比罗治疗金黄色葡萄球菌感染的药代动力学及药代/药效学（PK/PD）考量：系统评价 Camilla Genovese, Marta Colaneri, Enrico Sguazzini, Donatella Maddalena, ... Marta Ulldemolins Article 107959 3. Antibiotic resistance in Helicobacter pylori: pathogenic mechanisms and eradication barriers 幽门螺杆菌的抗生素耐药性：致病机制与根除障碍 Meenakshi Kandpal, Siddharth Singh, Harshita Shrivastava, Himanshi Jindal, ... Hem Chandra Jha Article 107981 4. Clinical pharmacology and therapeutic considerations of isavuconazole in special populations: A narrative review 艾沙康唑在特殊人群中的临床药理学特征与治疗考量：叙述性综述 Shichao Zhu, Rongsong Xia, Jing Yang, Fei Tang, ... Xuewen Qiu Article 108005 5. Nipah virus: An exceptionally virulent emerging zoonotic pathogen 尼帕病毒：一种高毒力新发人兽共患病病原体 Hao Sun, Xin Yuan, Jinyan Li, Xitang Li, ... Guangcai Duan Article 107990 6. Examining the global antimicrobial resistance surveillance landscape in food-producing animals 食用动物全球抗菌药物耐药性监测体系现状探析 Vika Li, Shaina Craig, Shabbir Simjee Article 108008 Full Length Articles（全文论著） 7. Proteomics reveals the mechanism by which sodium oleate decreases Escherichia coli susceptibility to gentamicin 蛋白质组学揭示油酸钠降低大肠埃希菌对庆大霉素敏感性的机制 Lvyuan Fan, Jingyun Wu, Ziyi Zhang, Liting Cai, ... Guozhu Ye Article 107989 8. Real-world use of liposomal amphotericin B: A large retrospective, observational, multicentre study 脂质体两性霉素 B 在现实中的应用：一项大型回顾性观察性多中心研究 Claudia Bartalucci, Daniele Roberto Giacobbe, Marco Muccio, Silvia Sisto, ... Giulia Viero Article 107952 9. Global burden of bacterial antimicrobial resistance among children under 5 years 1990−2021: A systematic analysis with forecasts to 2050 1990—2021年全球5岁以下儿童细菌耐药性疾病负担：系统分析及至2050年预测 Shanshan Wang, Fei Xie, Shaowei Sang Article 107995 10. Evaluation of vancomycin bolus/standard and continuous infusion on nephrotoxicity in a rat model 大鼠模型中万古霉素推注/常规给药与持续输注方案的肾毒性评价 Sylwia Marianski, Gwendolyn M. Pais, Colin Jeantet, Renz Paulo Melicor, ... Marc H. Scheetz Article 107988 11. Prevalence of third-generation cephalosporin-resistant Salmonella in animals in China: The key role of ESBL, AmpC, and other β-lactamase strains in the genome 我国动物源第三代头孢菌素耐药沙门菌流行情况：ESBL、AmpC 及其他 β- 内酰胺酶菌株在基因组中的关键作用 Fangqin Liu, Lu Zhang, Qi Zhao, Min Cheng, ... Chunping Zhang Article 107992 12. Real-world safety signals of fluoroquinolone-associated peripheral neuropathy: Analysis of US and Canadian databases combined with mechanistic exploration 氟喹诺酮类药物相关周围神经病变在现实中的安全信号：美、加数据库联合分析及机制探讨 Bingjian Guo, Ziwei Zou, Junfei Lu, Shimei Tan, Lingyan Mai Article 107993 13. Appropriate therapy and survival in carbapenem-resistant Enterobacterales bacteraemia: A multicentre cohort study on epidemiology and risk factors 碳青霉烯耐药肠杆菌科细菌菌血症的恰当治疗与生存率：一项关于流行病学及危险因素的多中心队列研究 Yae Jee Baek, Se Yoon Park, Jung Ho Kim, Hye Seong, ... Yoon Soo Park Article 108001 14. Ecological antagonism constrains receptor-diverse phage cocktail efficacy against multidrug-resistant Enterobacter hormaechei 生态拮抗作用限制受体多样性噬菌体鸡尾酒制剂对多重耐药霍氏肠杆菌的疗效 Bai-Ling Zhang, Ming-Yu Jiang, Xiu-Zhen Chen, Xiao-Qi Yang, ... Wei Chen Article 108004 15. Genomic epidemiology and resistance determinants of Pseudomonas aeruginosa in bronchiectasis across China: A multicentre study 全国支气管扩张患者铜绿假单胞菌的基因组流行病学及耐药决定因子研究：一项多中心研究 Linlin Xu, Qing Chen, Aikuang Ma, Kang Xu, ... Xiaoli Wang Article 108010 16. Pharmacovigilance signals and regional burden of antibiotic-associated Clostridioides difficile infection: A pharmacovigilance study and Global Burden of Disease Study 2023 药物警戒信号与抗生素相关艰难梭菌感染的区域疾病负担：一项药物警戒研究及 2023 年全球疾病负担研究 Dain Y. Kim, Hyunjeong Kim, Hyunyi Yoo, Hyoin Shin, ... Dong Keon Yon Article 108013 17. Aztreonam-avibactam activity against Enterobacterales from Asia Pacific and Latin American medical centres: Summary of 5 years of surveillance prior to clinical use (2020–2024) 氨曲南 - 阿维巴坦对亚太及拉美地区医疗机构肠杆菌目细菌的抗菌活性：临床应用前 5 年监测汇总（2020–2024） Helio S. Sader, Rodrigo E. Mendes, John H. Kimbrough, Krisztina M. Papp-Wallace, Mariana Castanheira Article 108003 18. Vancomycin population pharmacokinetics and optimized dosing in critically ill infants and children 危重症婴幼儿万古霉素群体药代动力学与优化给药方案 Tavey Dorofaeff, Xin Liu, Emmanuel Novy, Mark G. Coulthard, ... Jason A. Roberts Article 108006 19. Pulmonary penetration of intravenous rifabutin in healthy participants: A multiple-dose pharmacokinetic study 健康受试者静脉输注利福布汀的肺组织穿透性：一项多剂量药代动力学研究 Valentin al Jalali, Anselm Jorda, Lena Pracher, Amelie Leutzendorff, ... Markus Zeitlinger Article 108014 20. A clinical prediction model to support risk-adapted fibrinogen monitoring during tigecycline therapy: Multicentre development and validation 替加环素治疗期间用于风险分层纤维蛋白原监测的临床预测模型：多中心构建与验证 Jinlin Guo, Xinfeng Cai, Yayu Huo, Hongping Wen, ... Ruigang Hou Article 108012 Short Communications（短篇通讯） 21. Long-term treatment durability and safety after switching to bictegravir/emtricitabine/tenofovir alafenamide in real-world practice: a 144-week update from the BICTEL cohort 真实世界中换用比克替拉韦/恩曲他滨/丙酚替诺福韦后的长期疗效持久性与安全性：BICTEL队列144周更新数据 Luca Bortolani, Riccardo Donà, Antonietta Impellizzeri, Vlad Racolta, ... Gabriella d'Ettorre Article 107991 22. Daptomycin or linezolid versus vancomycin for the treatment of vancomycin-susceptible Enterococcus faecium bloodstream infections 达托霉素或利奈唑胺对比万古霉素治疗万古霉素敏感型屎肠球菌血流感染 Samantha Poloni, Timothée Klopfenstein, Adrien Biguenet, Mathieu Blot, ... Anne-Sophie Brunel Article 107994 23. Silent carriage of tigecycline- and carbapenem-resistant Klebsiella quasipneumoniae co-harbouring tet(X4) and blaNDM-1 in healthy individuals in China 国健康人群中携带tet(X4)与blaNDM-1基因的耐替加环素及碳青霉烯类准肺炎克雷伯菌的静默携带现象 Jing Wang, Zelin Yan, Heng Shen, Ling Xin, ... Rong Zhang Article 108009 24. Caspofungin pharmacokinetics in a child undergoing continuous veno-venous haemodiafiltration: A case report 接受连续性静脉 - 静脉血液透析滤过治疗患儿的卡泊芬净药代动力学：1 例病例报告 Noémie de Cacqueray, Agathe Béranger, Leo Froelicher Bournaud, Mathilde Grapin, ... Mehdi Oualha Article 108002 Letters to the Editor（致编辑信） 25. Comment on "stepwise within-host evolution of a blaCTX-M-27-positive Klebsiella pneumoniae clone under changing antimicrobial pressures leading to enhancement of β-lactam resistance" 评述《抗菌药物压力变化下产blaCTX-M-27肺炎克雷伯菌克隆株在宿主体内逐步进化并增强β内酰胺耐药性》 Evy Diah Woelansari, Sari Luthfiyah, Juliana Christyaningsih, Tacik Idayanti, Anita Dwi Anggraini Article 107987 26. blaNDM-4-carrying Klebsiella pneumoniae: an uncommon but epidemiologically informative signal in public genomes 携带blaNDM-4基因的肺炎克雷伯菌：公开基因组中一种少见但具流行病学提示价值的信号 Yan Feng, Yu Feng, Xiaoting Hua, Chao Zhuo, Zhiyong Zong Article 107982 27. Comment on “Aztreonam–avibactam pharmacokinetics during extracorporeal membrane oxygenation support: First insights from a case report” 对《体外膜肺氧合支持期间氨曲南 - 阿维巴坦的药代动力学：一则病例报告的初步探索》的评论 Guanghui Chen, Haibo Lei, Liang Long, Xiang Liu Article 107961 28. Comment on “The antiarrhythmic drugs dronedarone and amiodarone exhibit potent in vitro and in vivo activity against clostridioides difficile” 对《抗心律失常药物决奈达隆与胺碘酮在体内外均具有强大的艰难梭菌抑制活性》的评论 Zareena Begum Shaik, Thirupathi Gorre, Harikiran Lingabathula Article 107976 29. In reply to the letter to editor regarding ‘discrepancy between WGS-based genotypic and phenotypic drug susceptibility testing of first and second-line drugs for Mycobacterium tuberculosis: Limited impact of unknown resistance mechanisms’ 回复致编辑信：《结核分枝杆菌一线与二线药物基于全基因组测序的基因型药敏试验与表型药敏试验结果不一致：未知耐药机制的影响有限》 Peng Xu, Qian Gao Article 107999 30. In Reply to the Letter to Editor Regarding Tissue Pharmacokinetics of Antifungal Drugs: A Review 回复致编辑的信：《抗真菌药物的组织药代动力学：综述》 Felix Bergmann, Marlene Prager, Markus Zeitlinger Article 107996 31. In reply to letter to editor regarding ``a multicenter, randomised, double-blind, imipenem/cilastatin-controlled clinical study of cefiderocol for the treatment of complicated urinary tract infections caused by Gram-negative pathogens in Chinese adults'' 回复致编辑的信：《头孢地尔治疗中国成人革兰阴性菌所致复杂性尿路感染的多中心、随机、双盲、以亚胺培南 / 西司他丁为对照的临床研究》 Jinyi Yuan, Deyong Fan, Henglan Wu, Bei Jia, ... Yingyuan Zhang Article 107983 32. In reply to the Letter to the Editor regarding “Disrupting bacterial metabolism by targeting LDH reverses aminoglycoside resistance in Streptococcus suis” 针对《靶向乳酸脱氢酶干扰细菌代谢可逆转猪链球菌对氨基糖苷类药物的耐药性》一文致编者信的回复 Yang Wang, Shuji Gao, Baobao Liu, Yuxin Wang Article 108007 33. Comment on “Discrepancy between WGS-based genotypic and phenotypic drug susceptibility testing of first- and second-line drugs for Mycobacterium tuberculosis: Limited impact of unknown resistance mechanisms” 对《结核分枝杆菌一线及二线药物基于全基因组测序的基因型药敏试验与表型药敏试验结果不一致性：未知耐药机制的影响有限》一文的述评 Manish R. Bhise, Akshay Akotkar, Shweta Bhandari, Kuldip V. Gite Article 107997 34. Response to the Comment on ‘Burden and global distribution of antimicrobial resistance in nonbloodstream infections among adults with cirrhosis: A systematic review and proportional meta-analysis’ 针对《肝硬化成人非血流感染中抗菌药物耐药负担及全球分布：一项系统综述与比例 Meta 分析》一文评述的回复 Ellis K. Paintsil, Cansu Ozdemir, Tuhin Paul, Kasope Egoh, ... Debbie L. Shawcross Article 108019

微生物疗法临床研究

2026-10-20

·BioSpace

Basilea reports presentation of new data for fosmanogepix, isavuconazole and ceftobiprole at IDWeek 2026

Highlights include oral presentations of pediatric data from the fosmanogepix Expanded Access Program and the activity of its active moiety, manogepix, against Candida auris isolates Allschwil, Switzerland, October 20, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that new data on the phase 3 antifungal fosmanogepix, the antifungal isavuconazole (Cresemba ® ) and the antibiotic ceftobiprole (Zevtera ® ) will be presented at IDWeek 2026, which takes place from October 21 to 24 in Washington D.C., USA. Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “The breadth of data being presented at IDWeek across Basilea’s anti-infectives portfolio by us, our partners, collaborators and independent research groups, underscores the strong scientific interest in advancing the treatment of serious fungal and bacterial infections. These presentations continue to strengthen the evidence supporting our programs and their potential to address important unmet medical needs, including for pediatric patients.” Fosmanogepix data presented at IDWeek 2026 - Presentation: Fosmanogepix Expanded Access Experience in Pediatric Patients ≤11 Years of Age with Invasive Mold Infections Presenting author: L. E. Hastings Co-authors: K. L. Barros, M. L. Kussin, M. A. Kutny, J. B. Wood, Y. Vipulanandan, R. Banerjee, D. Dulek, T. S. Sharma, E. Kang, S. Maxwell, A. M. Green, D. Tyungu, M. M. Oldham, J. G. Lake, G. R. Alvira-Arill, E. Kitt, P. Gavin, N. DV De León, Y. Mozo del Castillo, E. Iosifidis, E. Roilides, D. S. Kohlfürst, J. Prattes, M. Hoenigl, O. O’Connor, J. Ryan, A. Howard-Jones, N. Maissen, V. A. Cruz Flores, H. Schlamm, K. Litherland, D. Ionescu, M. Engelhardt, E. Steletou, L. M. Kirkpatrick, J. C. Christenson, P. G. Pappas Date & time: Friday, October 23, 2026, 10:42-10:54 am Location: 201 - Presentation: Activity of manogepix against Candida auris isolates from the United States Presenting author: M. Winkler Co-authors: A. Klauer, S. Edeker, P. Rhomberg, M. Karr, H. Kimbrough, M. Castanheira Date & time: Friday, October 23, 2026, 4:15-4:30 pm Location: 103 AB - Poster #P-17: Activity of manogepix against Aspergillus spp. isolates with CYP51 alterations Presenting author: M. Winkler Co-authors: S. Edeker, A. Klauer, P. Rhomberg, M. Karr, H. Kimbrough, M. Castanheira Date & time: Thursday, October 22, 2026, 12:15-1:30 pm Location: Poster Hall B-C - Poster #P-18: Activity of manogepix against mold isolates across geographic regions Presenting author: M. Winkler Co-authors: S. Edeker, A. Klauer, P. Rhomberg, M. Castanheira Date & time: Thursday, October 22, 2026, 12:15-1:30 pm Location: Poster Hall B-C - Poster #P-19: Activity of manogepix against yeast and mold isolates from 2025 in the United States Presenting author: M. Winkler Co-authors: S. Edeker, A. Klauer, P. Rhomberg, M. Castanheira Date & time: Thursday, October 22, 2026, 12:15-1:30 pm Location: Poster Hall B-C Isavuconazole data presented at IDWeek 2026 - Rapid-Fire Poster Session: Isavuconazole versus Alternative Azoles for Invasive Aspergillus in Solid Organ Transplant Recipients [see also Poster #P-2022] Rapid Fire presenters: M. A. Colaluca, K. Marsh, Y. Li, C. Otto, M. Ringer Date & time: Friday, October 23, 2026, 12:30-12:35 pm Location: RF Arena 1 - Poster #P-31: Hepatotoxicity Signals Across Azole Antifungals: Is Isavuconazole Safer? A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Presenting author: V. Thiruvadi Co-authors: R. Ravichandran, Y. Kagzi, S. Ahsan, M. Alqaisieh, M. Kandula, D. Francisco Date & time: Thursday, October 22, 2026, 12:15-1:30 pm Location: Virtual Presentation - Poster #P-1645: Adoption of Isavuconazole in Pediatrics: A Multi-Center Survey Presenting author: C. Lan Co-authors: H. A. Jamal, M. Johnson, S. Vora Date & time: Thursday, October 22, 2026, 12:15-1:30 pm Location: Poster Hall B-C - Poster #P-1922: Evaluation of Inpatient Isavuconazole Prescribing Practices at a Community-Based Cancer Center Presenting author: W. Monier Texidor Co-authors: S. Kim, J. Unzaga, A. Ramos Morales, L. Kemp, L. Amaya Date & time: Friday, October 23, 2026, 12:15-1:30 pm Location: Poster Hall B-C - Poster #P-2005: Invasive aspergillosis in kidney transplant recipients: A 20-year cohort from Colombia Presenting author: I. Ramirez Co-author: C. Ruiz Date & time: Friday, October 23, 2026, 12:15-1:30 pm Location: Virtual presentation - Poster #P-2018: Epidemiology of Invasive Fungal Disease in Allogeneic Hematopoietic Cell Transplant Recipients at a Brazilian Cancer Center (2012–2022): Preliminary Data Presenting author: M. V. Batista Co-authors: A. Volpe, E. Veras; T. Monteiro-Silva, A. Luiza Marinho, B. Cal, A. Cordeiro, V. Bovolenta, M. Nascimento, J. Schmidt-Filho Date & time: Friday, October 23, 2026, 12:15-1:30 pm Location: Poster Hall B-C - Poster #P-2022: Isavuconazole versus Alternative Azoles for Invasive Aspergillus in Solid Organ Transplant Recipients Presenting author: M. A. Colaluca Co-authors: K. Marsh, Y. Li, C. Otto, M. Ringer Date & time: Friday, October 23, 2026, 12:15-1:30 pm Location: Poster Hall B-C - Poster #P-1372: Nationwide Retrospective Analysis of Isavuconazole Treatment for Histoplasmosis Presenting author: C. A. Gentry Co-authors: J. J. Farha, S. Thind, R. Williams, II Date & time: Saturday, October 24, 2026, 12:15-1:30 pm Location: Poster Hall B-C - Poster #P-1378: Effectiveness and Safety of Isavuconazole Compared with Posaconazole as Primary Antifungal Prophylaxis in High-risk Neutropenic Patients with Hematologic Malignancies and Allogeneic Hematopoietic Cell Transplantation Presenting author: F. Herrera Co-authors: D. Torres, N. Mañez, R. Jordán, J. Benso, M. Angel Alderete, Sr., N. Garcia Allende, G. A. Mendez, Sr., M. L. Pereya, L. Tula, A. Manzur, H. I. Peretti, El, C. Salgueira, M. Rodríguez Raimondo, F. Indo, S. Garcia Rojas, P. Callelo, M. Gabriel Castro, V. Fernandéz, A. Risso Patron, C. Niveyro, R. Gago, L. A. Luengo Ackermann, J. Afeltra Date & time: Saturday, October 24, 2026, 12:15-1:30 pm Location: Poster Hall B-C Ceftobiprole data presented at IDWeek 2026 - Poster #P-36: Pediatric Dose Selection of Ceftobiprole for Staphylococcus aureus Bacteremia, Including Right-Sided Infective Endocarditis Using Model-Based Approaches Presenting author: A. Tanudra Co-authors: C. Lim, K. Rana, C. M. Rubino, D. Lewis, K. B. Larson Date & time: Thursday, October 22, 2026, 12:15-1:30 pm Location: Poster Hall B-C - Poster #P-142: In vitro Activity of Ceftobiprole and Comparator Agents Against Contemporary US Clinical Isolates Collected in 2025 Following FDA Approval Presenting author: R. E. Mendes Co-authors: M. Winkler, S. H. Moussa, T. Wiktorowicz, H. Sader, M. Castanheira Date & time: Thursday, October 22, 2026, 12:15-1:30 pm Location: Poster Hall B-C - Poster #P-381: Extrapolation of Adult Efficacy and Safety to Support Pediatric Use of Ceftobiprole for Acute Bacterial Skin and Skin Structure Infections Presenting author: K. B. Larson Co-authors: R. Tummala, N. C. Close, C. M. Rubino, K. Rana, C. Lim, A. Tanudra, S. McLeod, S. Rege, D. Altarac, D. Lewis Date & time: Saturday, October 24, 2026, 12:15-1:30 pm Location: Poster Hall B-C For further information please visit . The fosmanogepix development program is funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration of Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under OT number: 75A50124C00033. The agreement and federal funding are not an endorsement of study results, product, or company. For Cresemba ® (isavuconazonium sulfate) 1 full U.S. prescribing information, please visit: For ZEVTERA ® (ceftobiprole medocaril sodium) 2 full U.S. prescribing information, please visit: Basilea’s ceftobiprole phase 3 program was funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201600002C. The contract and federal funding are not an endorsement of the study results, product, or company. Basilea was awarded approximately USD 111 million, or approximately 75 percent of the costs related to the Staphylococcus aureus bacteremia (SAB) and acute bacterial skin and skin structure infections (ABSSSI) phase 3 studies, regulatory activities and non-clinical work. About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com . Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For further information, please contact: Peer Nils Schröder, PhD Head of Corporate Communications & Investor Relations Basilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b 4123 Allschwil Switzerland Phone +41 61 606 1102 E-mail media_relations@basilea.com investor_relations@basilea.com This press release can be downloaded from . References Astellas Pharma Inc. is the organization responsible for commercializing Cresemba in the U.S. Innoviva Specialty Therapeutics is the organization responsible for commercializing Zevtera in the U.S. Attachment Press release (PDF)

临床3期引进/卖出

100 项与头孢比罗酯钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08886	头孢比罗酯钠	J01DI01	DB14733

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
社区获得性细菌性肺炎	美国	ISTx LLC	2024-04-03
右侧感染性心内膜炎	美国	ISTx LLC	2024-04-03
皮肤和皮肤结构感染	美国	ISTx LLC	2024-04-03
金黄色葡萄球菌菌血症	美国	ISTx LLC	2024-04-03
社区获得性肺炎	加拿大	Avir Pharma, Inc.	2018-03-20
医院获得性肺炎	加拿大	Avir Pharma, Inc.	2018-03-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
传染性皮肤病	申请上市	欧盟	Janssen Pharmaceutical Unlimited Co.	-
软组织感染	申请上市	欧盟	Janssen Pharmaceutical Unlimited Co.	-
新生儿败血症	临床3期	美国	Basilea Pharmaceutica AG	2023-08-06
新生儿败血症	临床3期	保加利亚	Basilea Pharmaceutica AG	2023-08-06
新生儿败血症	临床3期	爱沙尼亚	Basilea Pharmaceutica AG	2023-08-06
新生儿败血症	临床3期	德国	Basilea Pharmaceutica AG	2023-08-06
新生儿败血症	临床3期	拉脱维亚	Basilea Pharmaceutica AG	2023-08-06
新生儿败血症	临床3期	立陶宛	Basilea Pharmaceutica AG	2023-08-06
新生儿败血症	临床3期	波兰	Basilea Pharmaceutica AG	2023-08-06
新生儿败血症	临床3期	斯洛伐克	Basilea Pharmaceutica AG	2023-08-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06808646 (CTgov)	临床1期	药物相互作用	12	pitavastatin (Period 1; Pitavastatin 2 mg)	遞憲願衊艱構製遞艱廠(範齋夢壓鏇遞顧壓鹹齋) = 鏇獵壓選膚壓積鹹糧夢艱積網遞醖繭網築淵範 (鏇製範願蓋鹹繭膚製遞, 餘餘願築膚膚構鏇構壓 ~ 餘夢壓鹹淵糧鹹壓網網) 更多	-	2026-04-21
				pitavastatin+ceftobiprole (Period 2; Pitavastatin 2 mg Combined With Ceftobiprole 500 mg)	遞憲願衊艱構製遞艱廠(範齋夢壓鏇遞顧壓鹹齋) = 糧淵鬱齋網構夢廠顧醖艱積網遞醖繭網築淵範 (鏇製範願蓋鹹繭膚製遞, 夢範鹹獵遞醖獵鹹蓋蓋 ~ 淵鹹築淵鹹壓範鏇選鬱) 更多
NCT05856227 (CTgov)	临床3期	新生儿败血症	9	Ceftobiprole+ampicillin (Pre-term Neonates)	糧鑰鏇餘醖鹽蓋繭鏇築 = 繭餘窪範蓋積糧憲繭鏇鹹廠蓋鑰繭顧鏇範艱餘 (製糧積淵蓋廠網憲窪鹹, 淵鹽鏇醖選齋齋願鬱餘 ~ 積網窪鬱築網遞廠艱窪) 更多	-	2025-07-28
				Ceftobiprole+ampicillin (Term Neonates)	糧鑰鏇餘醖鹽蓋繭鏇築 = 淵夢齋憲壓醖積遞選遞鹹廠蓋鑰繭顧鏇範艱餘 (製糧積淵蓋廠網憲窪鹹, 齋繭鏇繭鬱窪醖憲鏇衊 ~ 鑰顧顧觸鹹積構壓鑰蓋) 更多
NCT03138733 (FDA_CDER) 人工标引	临床3期	金黄色葡萄球菌菌血症	387	ZEVTERA	廠壓積窪繭糧蓋窪獵獵(餘積遞積網蓋繭艱壓鑰) = 鹽憲膚憲餘廠築齋餘齋憲願繭醖廠醖簾膚鹽遞 (構醖餘鏇鬱餘夢窪繭廠 ) 更多	积极	2024-04-03
				Daptomycin	廠壓積窪繭糧蓋窪獵獵(餘積遞積網蓋繭艱壓鑰) = 鬱鏇窪積觸壓夢齋夢餘憲願繭醖廠醖簾膚鹽遞 (構醖餘鏇鬱餘夢窪繭廠 ) 更多
NCT03137173 (FDA_CDER) 人工标引	临床3期	皮肤和皮肤结构感染	679	ZEVTERA 667 mg	構觸製鏇餘網窪壓鬱襯(顧選鏇夢壓淵築艱憲繭) = 廠衊窪鏇壓範獵艱築糧襯齋願簾繭鑰襯願顧網 (齋觸範鬱廠餘艱簾簾繭 ) 更多	积极	2024-04-03
				Vancomycin plus aztreonam	構觸製鏇餘網窪壓鬱襯(顧選鏇夢壓淵築艱憲繭) = 襯繭願壓鬱廠夢襯淵鬱襯齋願簾繭鑰襯願顧網 (齋觸範鬱廠餘艱簾簾繭 ) 更多
NCT00326287 \| NCT03439124 (FDA_CDER) 人工标引	临床3期	社区获得性细菌性肺炎	-	Ceftobiprole medocaril (Adult Patients)	廠選壓醖艱壓顧鑰簾築(醖齋艱鏇壓齋觸齋憲選) = 鑰糧遞襯襯鏇夢選襯鏇齋艱艱遞積鑰觸襯鹹壓 (窪鑰顧簾範艱繭簾糧窪 ) 更多	积极	2024-04-03
				Ceftriaxone with or without Linezolid (Adult Patients)	廠選壓醖艱壓顧鑰簾築(醖齋艱鏇壓齋觸齋憲選) = 顧繭鏇願遞網襯簾壓憲齋艱艱遞積鑰觸襯鹹壓 (窪鑰顧簾範艱繭簾糧窪 ) 更多
NCT03138733 (ERADICATE, Pubmed)	临床3期	金黄色葡萄球菌菌血症	390	Ceftobiprole 500 mg IV every 6 hours for 8 days and every 8 hours thereafter	構艱鬱憲蓋膚醖獵艱鑰(獵鑰襯淵簾構簾壓夢遞) = 築鬱選製願窪繭鹹淵鏇淵鹹簾醖餘糧範襯憲製 (憲願淵糧觸網獵築襯糧 ) 更多	积极	2023-10-12
				Daptomycin 6 to 10 mg/kg IV every 24 hours plus optional aztreonam	構艱鬱憲蓋膚醖獵艱鑰(獵鑰襯淵簾構簾壓夢遞) = 淵觸願網簾製鹽獵憲鏇淵鹹簾醖餘糧範襯憲製 (憲願淵糧觸網獵築襯糧 ) 更多
NCT03138733 (Trial 1 \| ERADICATE, CTgov)	临床3期	金黄色葡萄球菌菌血症	390	Daptomycin	築顧窪願醖鏇鏇廠鹹夢 = 選醖壓鹹範艱夢製夢顧鹹夢構鹽膚願鹹艱繭襯 (鬱遞製簾積艱襯壓鏇艱, 網廠顧鬱憲網憲網壓齋 ~ 鹹築鹽網鹹構鹹壓構鹹) 更多	-	2023-05-06
NCT03138733 (ERADICATE, Corporate Publications) 人工标引	临床3期	金黄色葡萄球菌菌血症	390	Ceftobiprole Medocaril Sodium	鏇鑰鏇觸顧憲網選廠窪(壓齋觸製構鏇憲蓋構鑰) = 繭顧艱鹽獵築網齋鬱壓糧選餘憲齋獵壓廠窪夢 (製構憲襯鑰願範艱網蓋 ) 更多	非劣	2022-10-24
				Aztreonam+Daptomycin	鏇鑰鏇觸顧憲網選廠窪(壓齋觸製構鏇憲蓋構鑰) = 壓糧簾觸簾顧鑰鏇遞膚糧選餘憲齋獵壓廠窪夢 (製構憲襯鑰願範艱網蓋 ) 更多
NCT02527681 \| NCT03439124 (Pubmed \| Pediatr Infect Dis J)	N/A	-	-	Ceftobiprole (Neonates and infants up to 3 months of age)	鹽襯憲製蓋簾襯簾憲壓(選壓憲憲範繭獵餘顧艱) = 糧製壓憲範膚築網簾襯築衊積窪觸選簾壓壓齋 (襯憲鏇淵餘廠鹹衊窪艱 ) 更多	-	2021-11-01
				Ceftobiprole (Patients 3 months to 17 years of age)	鹽襯憲製蓋簾襯簾憲壓(選壓憲憲範繭獵餘顧艱) = 鹹獵範鑰顧鏇觸齋範襯築衊積窪觸選簾壓壓齋 (襯憲鏇淵餘廠鹹衊窪艱 ) 更多
NCT03137173 (TARGET, Pubmed \| Clin Infect Dis) 人工标引	临床3期	皮肤和皮肤结构感染	679	Ceftobiprole Medocaril Sodium	鬱構鹽鹽壓窪艱構構鬱(製衊蓋構醖觸壓淵醖選) = 選淵築製積顧簾選繭壓顧衊淵廠鏇廠淵鹹窪壓 (壓膚遞鑰鏇餘選繭鏇糧 ) 更多	非劣	2021-10-05
				Vancomycin Hydrochloride+Aztreonam	鬱構鹽鹽壓窪艱構構鬱(製衊蓋構醖觸壓淵醖選) = 選簾齋鑰遞遞製齋襯遞顧衊淵廠鏇廠淵鹹窪壓 (壓膚遞鑰鏇餘選繭鏇糧 ) 更多